molecules-logo

Journal Browser

Journal Browser

New Insights into Kinase Inhibitors II

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Bioorganic Chemistry".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 3852

Special Issue Editor


E-Mail Website1 Website2
Guest Editor
1. Experimental Pharmacology Laboratory, Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy
2. Dipartimento Salute della Donna e del Bambino, Università degli Studi di Padova, Padua, Italy
Interests: anticancer compounds; chemotherapy resistance; kinase inhibitors; antimitotic compounds; cancer pharmacology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This issue is a continuation of the previous successful Special Issue “New Insights into Kinase Inhibitors”.

In the last 30 years, kinases have been widely studied as drug targets to inhibit proliferation and angiogenesis in cancer therapy. Kinase inhibitors now represent one of the major classes of chemotherapeutics, with 52 kinase inhibitors having been approved as anticancer agents.

To date, 538 kinases are found to be active in the human body, where they are responsible for the phosphorylation of up to one-third of the proteome in controlling migration, survival, proliferation, and other processes via phosphorylation cascades. Moreover, aberrant kinase activity has been described to have an important role not only in cancer but also in inflammatory, degenerative, immunological, metabolic, and cardiovascular diseases.

Although their druggability and clinical safety profile make kinases attractive targets, the majority of kinases are still unexplored, and the field of kinase inhibitors is still growing.

This Special Issue will highlight new insights into the discovery of new kinase inhibitors, from the investigation of new targets to the identification of novel small molecules. Contributions to this issue, both in the form of original articles or reviews, may focus on powerful strategies and technological advances in the synthesis of more efficient and selective compounds, new strategies to overcome kinase inhibitors resistance, and improvements regarding the use of kinase inhibitors in oncology and other pathologies, in which therapeutic combinations with less toxic and off-target effects are considered.

Dr. Roberta Bortolozzi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • kinase inhibitors
  • kinase inhibitors chemistry
  • therapy resistance
  • combination therapy
  • antitumoral activity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issues

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2775 KiB  
Article
A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network
by Lidia Boghean, Sarbjit Singh, Kiran K. Mangalaparthi, Smitha Kizhake, Lelisse Umeta, Donn Wishka, Paul Grothaus, Akhilesh Pandey and Amarnath Natarajan
Molecules 2025, 30(9), 2001; https://doi.org/10.3390/molecules30092001 - 30 Apr 2025
Viewed by 126
Abstract
The quinoxaline core is found in several biologically active compounds, with Erdafitinib being the first FDA-approved quinoxaline derivative that targets a kinase and exhibits anti-cancer properties. We previously reported a quinoxaline analog (84) that displayed anti-cancer effects by inhibiting IKKβ, a [...] Read more.
The quinoxaline core is found in several biologically active compounds, with Erdafitinib being the first FDA-approved quinoxaline derivative that targets a kinase and exhibits anti-cancer properties. We previously reported a quinoxaline analog (84) that displayed anti-cancer effects by inhibiting IKKβ, a key kinase in the NFκB pathway. Here, we present the synthesis of a regioisomer (51-106) and its characterization as a selective MAP3K1 inhibitor with improved metabolic stability and oral bioavailability. We used the small molecule MAP3K1 inhibitor in a proteomics study that identified NPM1 as a member of the MAP3K1 network. Full article
(This article belongs to the Special Issue New Insights into Kinase Inhibitors II)
Show Figures

Graphical abstract

15 pages, 8550 KiB  
Article
In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones
by Kamonpan Sanachai, Panupong Mahalapbutr, Lueacha Tabtimmai, Supaphorn Seetaha, Nantawat Kaekratoke, Supakarn Chamni, Syed Sikander Azam, Kiattawee Choowongkomon and Thanyada Rungrotmongkol
Molecules 2023, 28(2), 597; https://doi.org/10.3390/molecules28020597 - 6 Jan 2023
Cited by 4 | Viewed by 2909
Abstract
Janus kinases (JAKs) are involved in numerous cellular signaling processes related to immune cell functions. JAK2 and JAK3 are associated with the pathogenesis of leukemia and common lymphoid-derived illnesses. JAK2/3 inhibitors could reduce the risk of various diseases by targeting this pathway. Herein, [...] Read more.
Janus kinases (JAKs) are involved in numerous cellular signaling processes related to immune cell functions. JAK2 and JAK3 are associated with the pathogenesis of leukemia and common lymphoid-derived illnesses. JAK2/3 inhibitors could reduce the risk of various diseases by targeting this pathway. Herein, the naphthoquinones were experimentally and theoretically investigated to identify novel JAK2/3 inhibitors. Napabucasin and 2′-methyl napabucasin exhibited potent cell growth inhibition in TF1 (IC50 = 9.57 and 18.10 μM) and HEL (IC50 = 3.31 and 6.65 μM) erythroleukemia cell lines, and they significantly inhibited JAK2/3 kinase activity (in a nanomolar range) better than the known JAK inhibitor, tofacitinib. Flow cytometric analysis revealed that these two compounds induced apoptosis in TF1 cells in a time and dose-dependent manner. From the molecular dynamics study, both compounds formed hydrogen bonds with Y931 and L932 residues and hydrophobically contacted with the conserved hinge region, G loop, and catalytic loop of the JAK2. Our obtained results suggested that napabucasin and its methylated analog were potential candidates for further development of novel anticancer drug targeting JAKs. Full article
(This article belongs to the Special Issue New Insights into Kinase Inhibitors II)
Show Figures

Graphical abstract

Back to TopTop